Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).
about
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients.Confocal laser endomicroscopy and immunoendoscopy for real-time assessment of vascularization in gastrointestinal malignancies.Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanismMagnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™.Relevant molecular markers and targets.Tumor lymphangiogenesis as a potential therapeutic target.Macrophage β2 integrin-mediated, HuR-dependent stabilization of angiogenic factor-encoding mRNAs in inflammatory angiogenesis.Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditionsA pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.Antiangiogenic properties of metronomic chemotherapy in breast cancer.Current status of antivascular therapy and targeted treatment in the clinic.Tumor angiogenesis: initiation and targeting - therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal adenocarcinomas -Targeting angiogenesis in childhood sarcomas.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Assessing tumor angiogenesis in colorectal cancer by quantitative contrast-enhanced endoscopic ultrasound and molecular and immunohistochemical analysis.miR-27a regulates endothelial differentiation of breast cancer stem like cells.The world of targeted therapies in kidney cancers: pitfalls, tips and tricks.Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma.
P2860
Q33395871-36E9D083-1F5B-4DB9-92F8-760678BEE91AQ33789194-1C90E603-9707-4CFB-89CB-539C75BACE07Q34213977-1DA48907-64EC-4808-9800-9F9FFE3A2287Q35061280-7228B971-8658-4786-BE6B-98073C7F059DQ35187503-A865875D-3709-4A93-AFF7-2F82C5A1892FQ35791117-945B1E4C-FDF7-4D91-833E-68F546B4F182Q35838122-9C659A67-4D88-43D8-9CFF-FE1670DD6161Q35952080-60C81205-CE21-4221-9358-829981B250B0Q35971694-89BA04A6-26D0-4635-A10E-21DB88C87258Q36615612-117152E3-A0EF-40D3-9CA6-31044A669E3CQ36768296-DAC773E2-FFD6-49C6-B91F-AF99BC2AE59BQ37063510-E4EB1504-F563-49A0-8CD6-E8D108999D19Q37341673-CEBAC77D-1742-47C1-BA7F-18674B33AC08Q37825441-87568C01-E048-4BFB-92F3-3F5F96532EECQ38113988-A5BF4488-62C8-41B5-B6AA-0EC9D5EA821AQ38689833-68A0D247-3458-4FCB-8021-CE9E941A685FQ39141651-99C46517-FEEE-4E68-AE75-2A5C5D86363DQ41991580-C1F80B58-92F3-453C-924D-4D8610EB88A7Q47229175-0555CCE0-4EA4-42BC-8E65-8DF1B58C15EA
P2860
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Angiogenesis and cancer: A cro ...... ls (the "do ut des" paradigm).
@ast
Angiogenesis and cancer: A cro ...... ls (the "do ut des" paradigm).
@en
type
label
Angiogenesis and cancer: A cro ...... ls (the "do ut des" paradigm).
@ast
Angiogenesis and cancer: A cro ...... ls (the "do ut des" paradigm).
@en
prefLabel
Angiogenesis and cancer: A cro ...... ls (the "do ut des" paradigm).
@ast
Angiogenesis and cancer: A cro ...... ls (the "do ut des" paradigm).
@en
P2093
P1476
Angiogenesis and cancer: A cro ...... ls (the "do ut des" paradigm).
@en
P2093
Ahmad Awada
Fabio Puglisi
Gilberto de Castro Junior
Nagi S El Saghir
P356
10.1016/J.CRITREVONC.2006.02.007
P577
2006-04-04T00:00:00Z